Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.66 |
| ▸ | KDR | P35968 | 7/20 | 0.65 |
| ▸ | FLT1 | P17948 | 6/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.65 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.61 |
| ▸ | FLT4 | P35916 | 2/20 | 0.59 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | TEC | P42680 | 1/20 | 0.58 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.58 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886926 | 0.95 | EGFR (0.70) | EGFRKDRFLT1ERBB2EPHA2 | |
| SCHEMBL3392679 | 0.93 | KDR (0.69) | EGFRKDRFLT1ERBB2EPHA2 | |
| SCHEMBL17179603 | 0.89 | EPHA2 (0.69) | EGFRKDRFLT1ERBB2EPHA2 | |
| SCHEMBL17179540 | 0.89 | EPHA2 (0.69) | EGFRKDRFLT1ERBB2EPHA2 | |
| SCHEMBL28105882 | 0.88 | KDR (0.67) | EGFRKDRFLT1ERBB2EPHA2 | |
| SCHEMBL28105879 | 0.88 | KDR (0.67) | EGFRKDRFLT1ERBB2EPHA2 | |
| SCHEMBL3134269 | 0.88 | EGFR (0.74) | EGFRKDRFLT1ERBB2EPHA2 | |
| SCHEMBL14843767 | 0.88 | EGFR (0.70) | EGFRKDRFLT1ERBB2EPHA2 | |
| SCHEMBL29453264 | 0.88 | EGFR (0.70) | EGFRKDRFLT1ERBB2EPHA2 | |
| Hydrochloric Acid SCHEMBL30264639 | 0.87 | ERBB2 (0.64) | EGFRKDRFLT1ERBB2EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167492-B1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI SCIENCE CO LTD (KR) | 2015-10-14 | — | — | EP | disclosed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | disclosed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | disclosed |
| EP-2167492-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | Hanmi Pharm. Co., Ltd. (KR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008150118-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDR 65/4885FLT1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.